ANAB · AnaptysBio, Inc.
$48.73
+1.31% last session
End-of-day data · close of 2026-10-23
Market cap
$1B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
9.6
Dividend yield
0.0%
Beta
0.45
Avg volume
1M
Employees
—
Daily Change %
1.31%
5 Days Change
-1.04%
10 Days Change
4.41%
30 Days Change
-5.74%
60 Days Change
-16.52%
Month to Day Change
0.21%
Year to Day Change
50.77%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ANAB
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-30
Latest call per bank · past 12 months
JP Morgan
Overweight$60.00
+23.1% vs priceUBS
Buy$76.00
+56.0% vs priceBarclays
Overweight$75.00
+53.9% vs priceWells Fargo
Overweight$81.00
+66.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-30 | JP Morgan | Maintains | Overweight | $70.00 → $60.00 |
| 2026-09-24 | HC Wainwright & Co. | Reiterates | Buy | $95.00 |
| 2026-09-23 | Leerink Partners | Maintains | Outperform | $90.00 → $81.00 |
| 2026-08-25 | TD Cowen | Maintains | Buy | $75.00 → $70.00 |
| 2026-08-24 | HC Wainwright & Co. | Reiterates | Buy | $95.00 |
| 2026-05-13 | UBS | Maintains | Buy | $60.00 → $76.00 |
| 2026-05-13 | Barclays | Maintains | Overweight | $63.00 → $75.00 |
| 2026-05-04 | Piper Sandler | Maintains | Overweight | $95.00 → $93.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 48 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 7.5% below the 50-day MA ($52.70).
- bearish: Price vs 200-day MA: Trading 2.5% below the 200-day MA ($49.96).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.45) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($22.06) and high ($69.81).
ANAB Price Chart
Loading chart for ANAB…
Fundamentals
About AnaptysBio, Inc.
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.